Amgen (AMGN) Convertible Debt (2009 - 2010)

Amgen (AMGN) recorded quarterly Convertible Debt of $2.2 billion in Q1 2010, down 51.22% quarter-over-quarter from $4.5 billion in Q4 2009.

Amgen (AMGN) Convertible Debt (2009 - 2010) Analysis & Trends

Amgen's Convertible Debt history runs 2 years deep, the most recent figure standing at $2.2 billion for Q1 2010.

In Q1 2010, Convertible Debt changed N/A year-over-year to $2.2 billion; the TTM figure through Mar 2010 stood at $2.2 billion (changed N/A YoY), while the FY2009 annual figure was $4.5 billion, changed N/A from the prior year.
Convertible Debt was $2.2 billion for Q1 2010 at Amgen, down from $4.5 billion in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $4.5 billion in Q4 2009 to a low of $2.2 billion in Q1 2010.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Gsk	93,699,046.73 Bn	93,699,041.77 Bn	7.76 Bn
2	Eli Lilly	1,012.06 Bn	1,006.77 Bn	16.22 Bn
3	Johnson & Johnson	560.67 Bn	538.62 Bn	15.96 Bn
4	AbbVie	402.20 Bn	392.85 Bn	10.78 Bn
5	Merck	298.59 Bn	292.94 Bn	12.09 Bn
6	Amgen	188.77 Bn	176.74 Bn	5.87 Bn
7	Gilead Sciences	160.22 Bn	152.49 Bn	5.52 Bn
8	Pfizer	148.19 Bn	135.42 Bn	-1.21 Bn
9	Bristol Myers Squibb	116.72 Bn	106.26 Bn	8.07 Bn
10	Novartis Ag	109.78 Bn	109.09 Bn	-

Download Data